Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the company.</li><li>Achieving robust growth in several segments, the company reported operational sales growth of 23% for the quarter and 18.5% for the year, with organic growth hitting 20% and 16% respectively.</li><li>These figures surpass their upper guidance limits, indicating strong market performance, driven primarily by the early U.S. adoption of the FARAPULSE system and other key products.</li></ul>

The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the company.Achieving robust growth in several segments, the company reported operational sales growth of 23% for the quarter and 18.5% for the year, with organic growth hitting 20% and 16% respectively.These figures surpass their upper guidance limits, indicating strong market performance, driven primarily by the early U.S. adoption of the FARAPULSE system and other key products.

Boston Scientific: How WATCHMAN and FARAPULSE Expansion Is Shaping This Med-Tech Giant’s Future!

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Back on the 23 December 2022, <strong><a href="https://www.smartkarma.com/entities/skyworth-group-limited" target="_blank" data-smartkarma-citation="entities:10941:1" rel="noopener">Skyworth Group (751 HK)</a></strong> announced (another) partial buyback, at HK$3.80/share, a 20.25% premium to undisturbed. On the 28 March, terms were bumped to $5.00/share. </li>
<li>At the <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0531/2023053101428.pdf" target="_blank" rel="noopener">close of the Offer</a>, the Wong Concert Group held 50.35%, and were no longer subject to the creeper rule. The Group now holds 56.04%</li>
<li>Yet another Partial Offer has been announced (HK$3.11/share, a 15.19% premium)), which will lift the Group's stake to 66.45%.  Minimum pro-ration is 37.84%. It is likely to go higher.</li>
</ul>


Back on the 23 December 2022, Skyworth Group (751 HK) announced (another) partial buyback, at HK$3.80/share, a 20.25% premium to undisturbed. On the 28 March, terms were bumped to $5.00/share. 
At the close of the Offer, the Wong Concert Group held 50.35%, and were no longer subject to the creeper rule. The Group now holds 56.04%
Yet another Partial Offer has been announced (HK$3.11/share, a 15.19% premium)), which will lift the Group's stake to 66.45%.  Minimum pro-ration is 37.84%. It is likely to go higher.


Skyworth Group (751 HK)'s Latest Partial Buyback. Thoughts On Proration

<ul><li>Boston Scientific Corporation presented its third quarter of 2024 financial results, reflecting a strong performance that exceeded company forecasts and investor expectations.</li><li>The corporation reported a significant growth in operational sales by 19% and organic sales by 18%, surpassing the anticipated guidance range of 13% to 15%.</li><li>Adjusted earnings per share (EPS) grew by 27% to $0.63, also exceeding the projections of $0.57 to $0.59.</li></ul>

Boston Scientific Corporation presented its third quarter of 2024 financial results, reflecting a strong performance that exceeded company forecasts and investor expectations.The corporation reported a significant growth in operational sales by 19% and organic sales by 18%, surpassing the anticipated guidance range of 13% to 15%.Adjusted earnings per share (EPS) grew by 27% to $0.63, also exceeding the projections of $0.57 to $0.59.

Boston Scientific's Game-Changing Farapulse Tech: How It's Revolutionizing Atrial Fibrillation Treatment!: - Major Drivers

<ul><li>Boston Scientific Corporation recently reported its second-quarter results, surpassing expectations with a strong performance driven by its cardiovascular portfolio and robust execution across multiple regions.</li><li>The company saw a remarkable 16% growth in operational sales, with organic sales climbing 15%, well above its projected range.</li><li>This growth was bolstered by innovation, clinical evidence, and strategic leadership in various categories.</li></ul>

Boston Scientific Corporation recently reported its second-quarter results, surpassing expectations with a strong performance driven by its cardiovascular portfolio and robust execution across multiple regions.The company saw a remarkable 16% growth in operational sales, with organic sales climbing 15%, well above its projected range.This growth was bolstered by innovation, clinical evidence, and strategic leadership in various categories.

Boston Scientific Corporation's Strategic Acquisitions and Portfolio Expansion: A Double-Edged Sword?

<ul><li>Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified product portfolio and effective execution across its various business units.</li><li>The company achieved an impressive 15% operationally and 13% organically in sales growth, surpassing the high-end guidance range of 7% to 9%.</li><li>Additionally, all business units and regions recorded notable double-digit growth during the quarter, reflecting strong market penetration and execution.</li></ul>

Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified product portfolio and effective execution across its various business units.The company achieved an impressive 15% operationally and 13% organically in sales growth, surpassing the high-end guidance range of 7% to 9%.Additionally, all business units and regions recorded notable double-digit growth during the quarter, reflecting strong market penetration and execution.

Boston Scientific Corporation: What Are Their Latest Investments in Innovative Technologies? - Major Drivers

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Boston Scientific: How WATCHMAN and FARAPULSE Expansion Is Shaping This Med-Tech Giant’s Future!

The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the...

Baptista Research

Skyworth Group (751 HK)'s Latest Partial Buyback. Thoughts On Proration

If the price gets (even) closer to the tender price, assuming investors want to come out short and expect no surprise shift in proration, it's...

David Blennerhassett

Boston Scientific's Game-Changing Farapulse Tech: How It's Revolutionizing Atrial Fibrillation Treatment!: - Major Drivers

Boston Scientific Corporation presented its third quarter of 2024 financial results, reflecting a strong performance that exceeded company...

Baptista Research

Boston Scientific Corporation's Strategic Acquisitions and Portfolio Expansion: A Double-Edged Sword?

Boston Scientific Corporation recently reported its second-quarter results, surpassing expectations with a strong performance driven by its...

Baptista Research

Boston Scientific Corporation: What Are Their Latest Investments in Innovative Technologies? - Major Drivers

Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)